Aptevo Therapeutics has adopted Genedata as their preferred bioinformatics solution provider. The American company will use the Genedata Biologics platform to facilitate the expansion of its novel bispecific antibody candidates focused on immuno-oncology, autoimmune disease and inflammation, according to a statement.
Genedata Biologics proved the best solution for increasing throughput, explained Dr. Peter Pavlik, Director of Molecular Biology and Protein Engineering Research at Aptevo. Specifically, the platform addresses all Aptevo’s unique workflow requirements, as it enables scale up of the screening, engineering, production and testing of multi-specific antibody candidates.
Since Genedata launched the platform in 2011, it has been adopted by the majority of the world’s leading biopharmaceutical companies. Its users also include emerging specialty biotech companies, according to the Basel company.
“We are excited to work with Aptevo, an innovative leader in the development of novel immunotherapies,” commented Genedata CEO Othmar Pfannes in the statement. “This partnership illustrates how Genedata works with future industry leaders who need a platform for scale up and automation of their R&D operations as they grow as an organization.”
